Is Gufic Biosciences a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Gufic Biosciences Ltd is a good quality company .

Is Gufic Biosciences undervalued or overvalued?

The key valuation ratios of Gufic Biosciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Gufic Biosciences share price return in the past 10 years?

Gufic Biosciences Ltd share price has appreciated 39.6% annually (CAGR) over the past ten years.

Is Gufic Biosciences a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Gufic Biosciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

Gufic Biosciences Ltd - Stock Valuation and Financial Performance

Name: Gufic Biosciences
Brand: Gufic Biosciences

BSE: 509079 | NSE: GUFICBIO | Pharmaceuticals & Drugs | Small Cap

Place order

Gufic Biosciences Share Price

₹431.55 -8.90 -2.02%
as on 20-Dec'24 16:59

10 Year X-Ray of Gufic Biosciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	18.4%	24.2%	24.3%	34.1%	29.7%	21%	30.1%	47.3%	23.2%	17.4%	-
Value Creation Index ⓘ	0.3	0.7	0.7	1.4	1.1	0.5	1.2	2.4	0.7	0.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	152	202	246	306	351	379	488	779	691	807	804
Sales YoY Gr.	-	33.4%	21.4%	24.5%	14.8%	8%	28.7%	59.8%	-11.4%	16.8%	-
Adj EPS ⓘ	0.6	1	1.1	1.9	2.8	2.4	4.5	9.8	8.4	8.7	8.5
YoY Gr.	-	76.8%	12.1%	74.8%	43.3%	-15.1%	89%	120.4%	-14.2%	3.4%	-
BVPS (₹) ⓘ	3.5	4.4	4.8	7	9.7	13.3	17.9	27.8	35.9	53.1	57.3
Adj Net Profit ⓘ	4.3	7.6	8.6	15.1	21.7	22.9	43.2	95.3	81.8	87.4	85
Cash Flow from Ops. ⓘ	11.2	-4.3	-4.1	-4.8	5.2	47.1	87.3	106	-26.6	-7.5	-
Debt/CF from Ops. ⓘ	2.9	-9.9	-13.7	-16.5	18.8	2.5	0.6	0.6	-11.7	-42.5	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	20.4%	18.1%	18.3%	16.8%
Adj EPS ⓘ	35.7%	25.7%	25%	3.4%
BVPSⓘ	35.3%	40.6%	43.7%	48%
Share Price	39.6%	48.3%	25.7%	33.6%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	16.2	25	24.2	33	33.5	22.3	28.5	43.1	26.5	19.9	15.4
Op. Profit Mgn % ⓘ	9.6	10	9.4	12.7	13.1	13.8	17.2	19	19.9	18.4	18.1
Net Profit Mgn % ⓘ	2.9	3.8	3.5	4.9	6.2	6	8.9	12.2	11.8	10.8	10.6
Debt to Equity ⓘ	1.2	1.3	1.5	1.5	1.3	0.9	0.3	0.2	0.9	0.6	0.2
Working Cap Days ⓘ	199	187	190	201	239	254	201	136	187	213	133
Cash Conv. Cycle ⓘ	23	40	67	86	73	84	47	31	55	91	51

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 18.26%

Net Profit is growing at healthy rate in last 3 years 25.04%

Debt to equity has declined versus last 3 years average to 0.60

Return on Equity has declined versus last 3 years average to 15.30%

Sales growth is not so good in last 4 quarters at 6.35%

Latest Financials - Gufic Biosciences Ltd.

	Standalone	Consolidated
TTM EPS (₹)	8.5	8.5
TTM Sales (₹ Cr.)	804	804
BVPS (₹.) ⓘ	57.3	57.3
Reserves (₹ Cr.) ⓘ	565	564
P/BV ⓘ	7.54	7.54
PE ⓘ	50.95	50.95

From the Market
52 Week Low / High (₹)	278.00 / 501.10
All Time Low / High (₹)	0.17 / 501.10
Market Cap (₹ Cr.)	4,327
Equity (₹ Cr.)	10
Face Value (₹)	1
Industry PE ⓘ	44.3

Management X-Ray of Gufic Biosciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Gufic Biosciences

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Gufic Biosciences

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	152	202	246	306	351	379	488	779	691	807
Operating Expenses ⓘ	137	183	223	267	305	327	404	631	556	661
Manufacturing Costs	19	27	32	41	47	51	57	93	87	108
Material Costs	73	91	107	129	161	156	226	368	295	339
Employee Cost	19	32	41	45	47	59	66	86	87	110
Other Costs ⓘ	26	33	42	52	50	60	55	84	86	105
Operating Profit ⓘ	14	20	23	39	46	52	84	148	135	146
Operating Profit Margin (%)	9.4%	9.7%	9.3%	12.7%	13.1%	13.8%	17.2%	19.0%	19.5%	18.1%
Other Income ⓘ	1	1	1	3	4	6	4	3	3	2
Interest ⓘ	4	6	6	9	10	14	14	5	8	15
Depreciation ⓘ	4	4	4	4	5	14	16	19	22	17
Exceptional Items ⓘ	0	0	0	2	0	0	0	0	0	0
Profit Before Tax ⓘ	7	10	14	30	35	30	58	127	107	116
Tax ⓘ	2	3	5	13	13	7	13	31	27	30
Profit After Tax	4	7	9	16	22	23	44	96	80	86
PAT Margin (%)	2.7%	3.6%	3.7%	5.4%	6.3%	6.0%	9.1%	12.3%	11.5%	10.7%
Adjusted EPS (₹)	0.5	1.0	1.2	2.1	2.8	2.3	4.6	9.9	8.2	8.6
Dividend Payout Ratio (%)	9%	5%	4%	2%	2%	2%	2%	1%	1%	1%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	27	34	37	54	75	129	173	269	348	533
Share Capital ⓘ	8	8	8	8	8	10	10	10	10	10
Reserves ⓘ	19	26	30	46	68	120	164	259	338	523
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	29	40	54	77	96	113	52	55	302	296
Long Term Debt	12	8	7	8	11	20	35	48	191	154
Short Term Debt	18	32	47	69	85	93	16	7	112	142
Trade Payables	50	53	44	76	78	117	111	141	130	166
Others Liabilities ⓘ	21	26	40	28	61	48	83	57	80	98
Total Liabilities ⓘ	127	152	175	235	310	407	419	521	860	1,093
Fixed Assets
Gross Block	51	51	26	31	37	115	149	180	246	246
Accumulated Depreciation	26	29	4	8	13	32	49	64	87	87
Net Fixed Assetsⓘ	25	22	22	23	24	83	100	115	160	159
CWIP ⓘ	0	0	0	2	10	31	13	41	170	307
Investmentsⓘ	0	0	0	0	0	0	0	0	1	2
Inventories	37	50	63	94	94	122	94	116	183	200
Trade Receivables	33	56	52	81	103	107	125	152	205	330
Cash Equivalents	6	6	6	7	8	16	13	27	47	13
Others Assetsⓘ	26	17	32	28	71	48	74	72	95	81
Total Assets ⓘ	127	152	175	235	310	407	419	521	860	1,093

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	11	-4	-4	-5	5	47	87	106	-27	-7
PBT ⓘ	7	11	14	30	35	30	58	127	107	116
Adjustment ⓘ	8	9	10	12	13	25	31	23	30	34
Changes in Working Capital ⓘ	-2	-21	-24	-30	-34	2	8	-11	-135	-130
Tax Paid ⓘ	-2	-3	-5	-16	-10	-10	-9	-33	-28	-27
Cash Flow From Investing Activity ⓘ	-2	-1	-5	-9	-13	-43	-7	-95	-191	-102
Capex	-3	-1	-4	-8	-13	-40	-12	-87	-188	-108
Net Investments	0	0	0	0	0	0	0	0	-1	-1
Others ⓘ	0	0	-1	-1	0	-3	6	-7	-2	7
Cash Flow From Financing Activityⓘ	-5	5	7	14	8	-4	-79	-6	234	82
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	100
Net Proceeds from Borrowing ⓘ	-3	-4	-1	1	3	7	12	12	107	-37
Interest Paid ⓘ	-4	-5	-6	-8	-10	-14	-13	-5	-8	-15
Dividend Paid ⓘ	0	0	0	0	0	0	0	-1	-1	-1
Others ⓘ	3	14	15	22	15	3	-77	-12	136	35
Net Cash Flow ⓘ	4	0	-1	1	0	0	2	5	17	-27

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	15.6	23.99	25.31	36.03	33.89	22.17	29.22	43.31	25.84	19.57
ROCE (%)	18.38	24.24	24.26	34.1	29.65	21.01	30.05	47.29	23.23	17.37
Asset Turnover Ratio	1.34	1.53	1.59	1.55	1.32	1.09	1.26	1.8	1.16	0.96
PAT to CFO Conversion(x)	2.75	-0.57	-0.44	-0.31	0.23	2.04	1.98	1.1	-0.34	-0.08
Working Capital Days
Receivable Days	70	76	76	76	93	98	81	59	81	104
Inventory Days	72	74	79	90	95	101	76	45	68	75
Payable Days	202	205	164	170	174	227	184	125	168	160

Gufic Biosciences Ltd Stock News

Gufic Biosciences Ltd FAQs

What is the share price of Gufic Biosciences?

Company share prices are keep on changing according to the market conditions. The closing price of Gufic Biosciences on 20-Dec-2024 16:59 is ₹431.6.

What is the market cap of Gufic Biosciences?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Gufic Biosciences stood at ₹4,327.5.

What is the P/E ratio of Gufic Biosciences?

The latest P/E ratio of Gufic Biosciences as of 20-Dec-2024 16:59 is 50.95.

What is the P/B ratio of Gufic Biosciences?

The latest P/B ratio of Gufic Biosciences as of 20-Dec-2024 16:59 is 7.54.

What is the 52-week high and low of Gufic Biosciences?

The 52-week high of Gufic Biosciences is ₹501.1 and the 52-week low is ₹278.0.

What is the TTM revenue of Gufic Biosciences?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Gufic Biosciences is ₹803.8 ( Cr.) .

About Gufic Biosciences Ltd

The company been in the Pharmaceutical industry since 1970 and is known and respected for Innovative and high Quality pharmaceutical and Herbal Products along with a wide range of APIs.

The company is one of the largest manufacturers of Lyophilized injections in India and has a fully automated lyophilization plant. Its lyophillized product portfolio includes Antibiotic, Antifungal, Cardiac, Infertility, Antiviral and proton-pump inhibitor segments.

The company’s products are supplied to most major hospital chains and leading medical facilities and it has an extensive network of representatives promoting these products all across India.

The company combines its high end Lyophilisation technology with R&D expertise to create differentiated products targeted at domestic and international markets. It has set up one of the largest and state of the art lyophilisation facility with major accreditations like EU-GMP, WHO-GMP, Ukraine-GMP.

Business area of the company

The company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

Products of the company

Pharmaceutical
Herbal
API / Bulk Drugs
Personal care
International

History and milestone

Past Initiatives

First Indian to produce Doxycycline Inj.
First Indian company to make Liquid Oxytetracycline Inj.
Mox (Amoxicillin) and Zole ointment featured among the top 100 pharma brands
First Company to launch Boswellia Serrata tablets
Pioneer in developing Kid tablet in India
Hived off Mox and Zole to Ranbaxy

2007-2009

Initiated contract manufacturing
Commenced international exports

2010-2015

Received patents for Anidulafungin and Tigecycline lyophilized inj.
Launched Criticare division

2016

Set up a full automatic state of the art facility at Navsari, India under the name Gufic Lifesciences Pvt ltd and received EU GMP approval
Launched Ferticare and Criticare Life divisions

2017-2019

Received patents for Rifabutin and Micafunginlyophilized inj.
Exported Vancomycin lyophilized Inj. to Germany
Manufacturing capacity ramped up to 31 million vials per annum
Launched Ferticare Life division

2020

Manufacturing Remdesivir for Hetero
Increased capacity to 48 million vials per annum

2022

Incorporated wholly owned subsidiary company namely ‘Gufic UK’
Received DCGI approval for Thymosin Alpha-1 (Immunocin - A Brand of Gufic for the said drug)